| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2020―Mar―12 |
Safety and Immunity of Covid-19 aAPC Vaccine |
|
| 2 |
[GO] |
2020―Mar―12 |
Accurate Classification System for Patients With COVID-19 Pneumonitis |
|
| 3 |
[GO] |
2020―Mar―12 |
Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019 |
|
| 4 |
[GO] |
2020―Mar―12 |
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells |
|
| 5 |
[GO] |
2020―Mar―10 |
Prognostic Factors of Patients With COVID-19 |
|
| 6 |
[GO] |
2020―Mar―10 |
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 |
|
| 7 |
[GO] |
2020―Mar―10 |
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) |
|
| 8 |
[GO] |
2020―Mar―10 |
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19 |
|
| 9 |
[GO] |
2020―Mar―10 |
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment |
|
| 10 |
[GO] |
2020―Mar―10 |
Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia |
|
| 11 |
[GO] |
2020―Mar―10 |
Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus |
|
| 12 |
[GO] |
2020―Mar―10 |
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus |
|
| 13 |
[GO] |
2020―Mar―10 |
Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 |
|
| 14 |
[GO] |
2020―Mar―10 |
Evaluation of Ganovo Combined With Ritonavir in the Treatment of Novel Coronavirus Infection |
|
| 15 |
[GO] |
2020―Mar―10 |
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) |
|
| 16 |
[GO] |
2020―Mar―10 |
Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients |
|
| 17 |
[GO] |
2020―Mar―10 |
Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus |
|
| 18 |
[GO] |
2020―Mar―01 |
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 |
|
| 19 |
[GO] |
2020―Mar―01 |
The Clinical Study of Carrimycin on Treatment Patients With COVID-19 |
|
| 20 |
[GO] |
2020―Mar―01 |
Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) |
|
| 21 |
[GO] |
2020―Mar―01 |
Eculizumab (Soliris) in Covid-19 Infected Patients |
|
| 22 |
[GO] |
2020―Feb―27 |
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 |
|
| 23 |
[GO] |
2020―Feb―26 |
Safety and Immunogenicity Study of 2019-nCov Vaccine (mRNA-1273) to Treat Novel Coronavirus |
|
| 24 |
[GO] |
2020―Feb―26 |
Humanistic Care in Patients With Coronavirus Disease 2019 |
|
| 25 |
[GO] |
2020―Feb―26 |
Humanistic Care in Healthcare Workers in Coronavirus Disease 2019 |
|
| 26 |
[GO] |
2020―Feb―26 |
A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection |
|
| 27 |
[GO] |
2020―Feb―26 |
Study for Novel Coronavirus Pneumonia (NCP) |
|
| 28 |
[GO] |
2020―Feb―26 |
CT Scores Predict Mortality in 2019-nCoV Pneumonia |
|
| 29 |
[GO] |
2020―Feb―25 |
A New Screening Strategy for 2019 Novel Coronavirus Infection |
|
| 30 |
[GO] |
2020―Feb―22 |
Fingolimod in COVID-19 |
|
| 31 |
[GO] |
2020―Feb―22 |
The Investigation of the Neonates With or With Risk of COVID-19 |
|
| 32 |
[GO] |
2020―Feb―22 |
Adaptive COVID-19 Treatment Trial |
|
| 33 |
[GO] |
2020―Feb―22 |
Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations |
|
| 34 |
[GO] |
2020―Feb―22 |
Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection |
|
| 35 |
[GO] |
2020―Feb―22 |
NK Cells Treatment for Novel Coronavirus Pneumonia |
|
| 36 |
[GO] |
2020―Feb―22 |
Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu |
|
| 37 |
[GO] |
2020―Feb―21 |
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 |
|
| 38 |
[GO] |
2020―Feb―20 |
The COVID-19 Mobile Health Study (CMHS) |
|
| 39 |
[GO] |
2020―Feb―20 |
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia |
|
| 40 |
[GO] |
2020―Feb―20 |
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia |
|
| 41 |
[GO] |
2020―Feb―20 |
A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia |
|
| 42 |
[GO] |
2020―Feb―20 |
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia |
|
| 43 |
[GO] |
2020―Feb―20 |
Function and Safety Study of SARS-CoV-2 Synthetic Minigene Vaccines |
|
| 44 |
[GO] |
2020―Feb―20 |
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment |
|
| 45 |
[GO] |
2020―Feb―18 |
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children |
|
| 46 |
[GO] |
2020―Feb―18 |
Clinical Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China |
|
| 47 |
[GO] |
2020―Feb―14 |
Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia |
|
| 48 |
[GO] |
2020―Feb―14 |
Immunoregulatory Therapy for 2019-nCoV |
|
| 49 |
[GO] |
2020―Feb―12 |
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia |
|
| 50 |
[GO] |
2020―Feb―12 |
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients |
|
| 51 |
[GO] |
2020―Feb―11 |
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection |
|
| 52 |
[GO] |
2020―Feb―11 |
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia |
|
| 53 |
[GO] |
2020―Feb―08 |
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus |
|
| 54 |
[GO] |
2020―Feb―08 |
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection |
|
| 55 |
[GO] |
2020―Feb―08 |
A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia |
|
| 56 |
[GO] |
2020―Feb―08 |
Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) |
|
| 57 |
[GO] |
2020―Feb―08 |
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia |
|
| 58 |
[GO] |
2020―Feb―08 |
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia |
|
| 59 |
[GO] |
2020―Feb―07 |
Severe 2019-nCoV Remdesivir RCT |
|
| 60 |
[GO] |
2020―Feb―06 |
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus |
|
| 61 |
[GO] |
2020―Feb―06 |
The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection |
|
| 62 |
[GO] |
2020―Feb―06 |
Washed Microbiota Transplantation for Patients With Coronavirus Pneumonia |
|
| 63 |
[GO] |
2020―Feb―06 |
Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of 2019-nCoV |
|
| 64 |
[GO] |
2020―Feb―06 |
Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV |
|
| 65 |
[GO] |
2020―Feb―06 |
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection |
|
| 66 |
[GO] |
2020―Feb―06 |
2019-nCoV Outbreak and Cardiovascular Diseases |
|
| 67 |
[GO] |
2020―Feb―06 |
A Prospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia |
|
| 68 |
[GO] |
2020―Feb―06 |
A Prospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia |
|
| 69 |
[GO] |
2020―Feb―06 |
Mild/Moderate 2019-nCoV Remdesivir RCT |
|
| 70 |
[GO] |
2020―Jan―30 |
A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV) |
|
| 71 |
[GO] |
2020―Jan―30 |
Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV |
|
| 72 |
[GO] |
2020―Jan―29 |
Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure |
|
